Navigation Links
Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results
Date:8/16/2010

NASHVILLE, Tenn., Aug. 16 /PRNewswire-FirstCall/ --- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announces financial results for the second quarter ending June 30, 2010, and provides revenue guidance for full year 2010.

Net Revenue:  For the three months ended June 30, 2010, net revenue was $10.7 million, up 9% from $9.8 million for the same period in 2009. This increase was primarily attributable to increased revenue from Acetadote. Net revenue for the six months ended June 30, 2010, was $20.9 million, up 9% from $19.2 million for the corresponding prior year period. This increase was also primarily due to an increase in Acetadote revenue over the prior year period.

Operating Expenses:  Total operating expenses for the three months ended June 30, 2010, were $9.7 million compared with $9.2 million for the same period in 2009. This increase was due to a 33% increase in sales and marketing expense, from $4.4 million in the second quarter 2009 to $5.8 million in the second quarter 2010, and was primarily due to the expansion of the Company's hospital sales force for the launch of Caldolor. That increase was offset by a reduction in research and development expense, from $2.6 million in the second quarter 2009 to $1.0 million in the second quarter 2010 due to a milestone expense related to FDA approval of Caldolor in June 2009.

Operating expenses for the six-month period ended June 30, 2010, were $19.1 million compared with $16.5 million for the same period in 2009. This was due to the aforementioned increase in selling and marketing expense from expansion of the Company's hospital sales force offset by the decrease in expense related to research and development.

Net Income:  Net income for the three months
'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Cumberland Pharmaceuticals to Present at the Wells Fargo Healthcare Conference in Boston on June 23, 2010
2. Cumberland Pharmaceuticals to Present at Jefferies Global Life Sciences Conference in New York on June 8, 2010
3. Cumberland Pharmaceuticals To Announce First Quarter 2010 Financial Results on May 13, 2010
4. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
5. Cumberland Pharmaceuticals Reports 24% Increase in Net Revenue With Full Year 2009 Financial Results
6. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
7. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
8. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
9. Ferring Pharmaceuticals FIRMAGON® Joins Race to End Prostate Cancer as Official Sponsor of the Great Prostate Cancer Challenge / Dash for Dad
10. Jiangbo Pharmaceuticals Announces the Commercial Launch of Felodipine Sustained Release Tablets
11. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014  Based on its recent analysis of ... & Sullivan recognizes MobileHelp with the 2014 North ... Value Leadership. MobileHelp,s leadership in flexibility across in-home ... progression in personal emergency response, and exemplifies key ... MobileHelp is at the forefront of convenience ...
(Date:7/29/2014)... , July 29, 2014 ... Austria will present data from a Phase ... aims to slow or stop Parkinson,s disease progression. The ... $ 1.5 million grant and will discuss the impact of ... When:   Thursday, July 31, 2014 ...
(Date:7/29/2014)... July 29, 2014   Abide Therapeutics ... to its board of directors. Thornberry was ... and Endocrinology for Merck & Co. Inc., where ... pipeline management in diabetes, osteoporosis, fertility and contraception. ... the program that resulted in the discovery of ...
Breaking Medicine Technology:Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 2Abide Therapeutics Appoints Nancy Thornberry to Board of Directors 3
... ... Release Formulation, CHICAGO, April ... sustained-release investigational compound to treat,Restless Legs Syndrome (RLS), showed that ... placebo, and was,generally well-tolerated when administered once-daily for 12 weeks., ...
... Expansion of Company,s Phase 3 Study for Wet AMD after ... 90-day Review ... announced,today that the U.S. Food and Drug Administration (FDA) has granted ... Phase 3 trial from 10 to 30 in the United States. ...
Cached Medicine Technology:Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 2Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 3Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 4Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 5Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome 6FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 2FDA Grants NeoVista's Request to Expand CABERNET Trial to 30 Sites in the U.S. 3
(Date:7/29/2014)... (PRWEB) July 30, 2014 Saint ... recently been awarded the Patient-Centered Medical Home 2011 ... National Committee for Quality Assurance. Only one out ... Level I, Level 2, or Level 3 recognition. ... in Patient-Centered Medical Home report faster access to ...
(Date:7/29/2014)... VogueQueen.com, a well-known online supplier, now ... trends in garment fashion by providing graceful and sexy ... an all-inclusive array of sexy dresses , designed ... lot of customers take price into consideration. Worry no ... the purchase more affordable for all clients. , ...
(Date:7/29/2014)... a form of acupuncture where a small ... needles produces significant improvements in fatigue, anxiety ... for early stage breast cancer patients experiencing joint ... (AIs) to treat breast cancer. The results of ... by researchers at the Perelman School of Medicine ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Diabetes is a ... is developed, blood sugar levels are increased, while the production ... produced by the pancreas and which is needed by the ... to overcome and can be very dangerous, as there are ... To learn more about this disorder and read a complex ...
(Date:7/29/2014)... DailyGossip.org reveals in its Stop Sciatica ... new method of naturally overcoming sciatica, in less than ... method ensure sufferers that the cure is simple to ... The new method is described as very fast, as ... an 8 minutes per day treatment plan. , ...
Breaking Medicine News(10 mins):Health News:Saint Luke’s Medical Group Awarded Patient-Centered Medical Home 2011 Level 3 Recognition 2Health News:VogueQueen.com Now Provides Graceful And Sexy Lingerie Collection For August 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 2Health News:Acupuncture improves quality of life for breast cancer patients using aromatase inhibitors 3Health News:Reverse Your Diabetes Today Review Exposes Matt Traverso’s New eBook 2Health News:Stop Sciatica in 8 Minutes Review Reveals the Way to Cure Sciatica Easily 2
... found in foods, study shows , FRIDAY, Aug. 14 ... choline during pregnancy increases the risk of brain and ... focused on two types of neural tube birth defects ... condition in which the brain and skull don,t develop, ...
... named one of the top 10 hospital systems in the ... a leading business and professional information organization based in New ... systems outperformed their peers by a wide margin. They ... more lives, had fewer patient complications, and made fewer patient ...
... , ... On Oct. 9-10, 2009, CRSA will hold ... the organization. An estimated 300 surgeons will be in attendance ... applications for gastrointestinal, colorectal, vascular, transplant, endocrine, oncology and bariatrics. Those ...
... Mich., Aug. 14 Work and economy related stress is taking ... independent survey conducted by American Laser Centers, the largest provider of ... respondents who took part in the survey (47 percent) currently feel ... , , The physical toll of their ...
... /PRNewswire-FirstCall/ - Hard to Treat Diseases, Inc. (HTDS:PK), ... great progress being made with the experimental findings ... cure of Multiple Sclerosis not only in their ... unauthorized news link) , , http://www.ctv.ca/servlet/ArticleNews/story/CTVNews/20090812/mtl_090812/20090812?hub=Health ...
... , , SAN FRANCISCO, Aug. ... few have success rates higher than 50 percent and none have been ... r al H e alth International (NHI), ... today, its Femmenessence line has been clinically proven to alleviate ...
Cached Medicine News:Health News:University Hospitals in Cleveland named one of the top 10 hospital systems in United States 2Health News:International Robotic Surgery Forum Launches In Chicago 2Health News:International Robotic Surgery Forum Launches In Chicago 3Health News:Hard To Treat Diseases (HTDS.PK) Scientists present encouraging results for the future of Multiple Sclerosis treatment. 2Health News:Hard To Treat Diseases (HTDS.PK) Scientists present encouraging results for the future of Multiple Sclerosis treatment. 3Health News:Hard To Treat Diseases (HTDS.PK) Scientists present encouraging results for the future of Multiple Sclerosis treatment. 4Health News:When it Comes to Natural Remedies for Hormonal Balance, the Proof is in the Clinical Research 2
Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Designed to use all advantages of bipolar technique. C-2600 MP recommended to all specialties that uses the benefits of the bipolar techniques....
Medicine Products: